Technical Analysis for CRBU - Caribou Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -5.57% | |
| 20 DMA Resistance | Bearish | -6.87% | |
| Bollinger Band Squeeze | Range Contraction | -6.87% | |
| Gapped Up | Strength | -6.87% | |
| 20 DMA Resistance | Bearish | -6.87% |
| Alert | Time |
|---|---|
| Down 5% | 3 days ago |
| New 52 Week Low | 3 days ago |
| Lower Bollinger Band Support | 3 days ago |
| Fell Below Lower Bollinger Band | 3 days ago |
| Down 3% | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.5899 |
| 52 Week Low | 3.365 |
| Average Volume | 1,802,339 |
| 200-Day Moving Average | 5.36 |
| 50-Day Moving Average | 4.44 |
| 20-Day Moving Average | 3.70 |
| 10-Day Moving Average | 3.62 |
| Average True Range | 0.26 |
| RSI (14) | 31.97 |
| ADX | 32.76 |
| +DI | 11.56 |
| -DI | 24.69 |
| Chandelier Exit (Long, 3 ATRs) | 3.44 |
| Chandelier Exit (Short, 3 ATRs) | 4.13 |
| Upper Bollinger Bands | 3.99 |
| Lower Bollinger Band | 3.41 |
| Percent B (%b) | -0.04 |
| BandWidth | 15.47 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.30 |
| MACD Histogram | 0.0423 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.80 | ||||
| Resistance 3 (R3) | 3.84 | 3.74 | 3.73 | ||
| Resistance 2 (R2) | 3.74 | 3.63 | 3.72 | 3.71 | |
| Resistance 1 (R1) | 3.56 | 3.57 | 3.51 | 3.53 | 3.69 |
| Pivot Point | 3.46 | 3.46 | 3.44 | 3.45 | 3.46 |
| Support 1 (S1) | 3.29 | 3.36 | 3.24 | 3.25 | 3.09 |
| Support 2 (S2) | 3.19 | 3.30 | 3.17 | 3.07 | |
| Support 3 (S3) | 3.02 | 3.19 | 3.05 | ||
| Support 4 (S4) | 2.98 |
